XPhyto Therapeutics Corp. announced the successful validation of their point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. European regulatory approval and commercial product launch in European markets are planned for first quarter 2021. The newly developed SARS-CoV-2 RT-PCR test system has demonstrated diagnostic level accuracy (sensitivity and specificity) in its ability to detect SARS-CoV-2 RNA within 25 minutes. Robustness, repeatability, and laboratory precision have also been confirmed. The test is designed to be conducted with only minimal laboratory processes and equipment.